Fildes J E, Shaw S M, Williams S G, Yonan N
The Transplant Centre, University Hospital of South Manchester NHS Foundation Trust, Wythenshawe Hospital, Manchester, UK.
Cancer Immunol Immunother. 2009 Mar;58(3):461-7. doi: 10.1007/s00262-008-0541-2. Epub 2008 Jun 4.
3-hydroxy-3-methyglutaryl CoA reductase inhibitors (statins) are frequently used following organ transplantation and have well reported pleiotropic effects, including immunomodulation, which may be of benefit in preventing graft rejection. However, the immunomodulatory effects of statins on cell transformation and malignancy, combined with the immunologic processes and administration of immunosuppression are almost completely unknown. The administration of immunosuppression is well recognised as the main cause of cancer following transplantation, so the addition of an immunomodulatory agent should be associated with an increased incidence of cancer, as immune surveillance and response may be suppressed, allowing cellular transformation and proliferation combined with lack of recognition to occur. This hypothetical review attempts to delineate the mode of action of statins in terms of pro/anti-carcinogenic mechanisms, while considering graft rejection and the presence of immunosuppression.
3-羟基-3-甲基戊二酰辅酶A还原酶抑制剂（他汀类药物）常用于器官移植后，并且有充分报道显示其具有多效性作用，包括免疫调节，这可能对预防移植排斥有益。然而，他汀类药物对细胞转化和恶性肿瘤的免疫调节作用，与免疫过程及免疫抑制的应用几乎完全未知。免疫抑制的应用被公认为移植后癌症的主要原因，因此添加一种免疫调节药物应该会增加癌症的发生率，因为免疫监视和反应可能会受到抑制，从而使细胞转化和增殖以及缺乏识别得以发生。这篇假设性综述试图从促癌/抗癌机制方面描述他汀类药物的作用方式，同时考虑移植排斥和免疫抑制的存在。
